Sedation during bronchoscopy: data from a nationwide sedation and monitoring survey by Gaisl, Thomas et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Sedation during bronchoscopy: data from a nationwide sedation and
monitoring survey
Gaisl, Thomas; Bratton, Daniel J; Heuss, Ludwig T; Kohler, Malcolm; Schlatzer, Christian; Zalunardo,
Marco P; Frey, Martin; Franzen, Daniel
Abstract: BACKGROUND: There is limited knowledge on practice patterns in procedural sedation and
analgesia (PSA), the use of propofol, and monitoring during flexible bronchoscopy (FB). The purpose of
this study was to assess the current practice patterns of FBs and to focus on the use of propofol, the
education of the proceduralist, and the involvement of anaesthesiologists during FB. METHODS: An
anonymous questionnaire was sent to 299 pulmonologists. Only respondents who were active physicians
in adult respiratory medicine performing FB were subsequently analysed. RESULTS: The response rate
was 78 % and 27,149 FB in the previous 12 months were analysed. The overall sedation-related morbidity
rate was 0.02 % and mortality was 7/100’000 FB. Sedation was used in 95 % of bronchoscopies. The
main drugs used for PSA were propofol (77 %) and midazolam (46 %). In 84 % of PSAs propofol
was used without the attendance of an anaesthesiologist. The use of propofol was associated with high
volume bronchoscopists (p < 0.010) and career-young pulmonologists (p < 0.001). While monitoring
vital parameters has become standard practice, pulmonologists reported a very low rate of systematic
basic education and training in the field of PSA (50 %). CONCLUSIONS: In Switzerland, PSA during
FB is mostly performed with propofol without the attendance of an anaesthesiologist and the use of this
drug is expected to increase in the future. While monitoring standards are very high there is need for
policies to improve education, systematic training, and support for pulmonologists for PSA during FB.
DOI: 10.1186/s12890-016-0275-4
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-131044
Veröffentlichte Version
 
 
Originally published at:
Gaisl, Thomas; Bratton, Daniel J; Heuss, Ludwig T; Kohler, Malcolm; Schlatzer, Christian; Zalunardo,
Marco P; Frey, Martin; Franzen, Daniel (2016). Sedation during bronchoscopy: data from a nationwide
sedation and monitoring survey. BMC Pulmonary Medicine, 16(1):113. DOI: 10.1186/s12890-016-0275-4
RESEARCH ARTICLE Open Access
Sedation during bronchoscopy: data from a
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Abstract
Background: There is limited knowledge on practice patterns in procedural sedation and analgesia (PSA), the use
of propofol, and monitoring during flexible bronchoscopy (FB). The purpose of this study was to assess the current
practice patterns of FBs and to focus on the use of propofol, the education of the proceduralist, and the
involvement of anaesthesiologists during FB.
Methods: An anonymous questionnaire was sent to 299 pulmonologists. Only respondents who were active
physicians in adult respiratory medicine performing FB were subsequently analysed.
Results: The response rate was 78 % and 27,149 FB in the previous 12 months were analysed. The overall sedation-
related morbidity rate was 0.02 % and mortality was 7/100’000 FB. Sedation was used in 95 % of bronchoscopies.
The main drugs used for PSA were propofol (77 %) and midazolam (46 %). In 84 % of PSAs propofol was used
without the attendance of an anaesthesiologist. The use of propofol was associated with high volume
bronchoscopists (p < 0.010) and career-young pulmonologists (p < 0.001). While monitoring vital parameters has
become standard practice, pulmonologists reported a very low rate of systematic basic education and training in
the field of PSA (50 %).
Conclusions: In Switzerland, PSA during FB is mostly performed with propofol without the attendance of an
anaesthesiologist and the use of this drug is expected to increase in the future. While monitoring standards are
very high there is need for policies to improve education, systematic training, and support for pulmonologists for
PSA during FB.
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Background
Flexible bronchoscopy (FB) is still the gold standard for
numerous diagnostic and therapeutic interventions and
has become an integral part of pulmonary medicine [1].
Sedatives or anaesthetics are a prerequisite for proced-
ural tolerance and patient satisfaction [2–4] and thus
they are widely used during the procedure [5]. In general
they are considered safe [6] and in the absence of contra-
indications expert panels explicitly recommend the use of
moderate sedation in patients undergoing FB [7–9].
FB is now increasingly performed outside the operating
theatre and outside high output tertiary care centres, which
has gone hand in hand with a shift in procedural sedation
and analgesia (PSA) practice [10]. Historically, anesthesiolo-
gists have been predominantly in charge of PSA, but a
growing number of proceduralists are managing sedation
and anesthesia during FB. This has created debate
about bronchoscopist-administered vs. anesthesiologist-
administered sedation during bronchoscopy.
Because common complications during FB (e.g. re-
spiratory depression, cardiovascular instability) and one-
half of deaths reported during FB are related to sedation,
the quality of education, experience and skills of mem-
bers of the bronchoscopy team are instrumental in
maintaining a good safety profile for FB [3]. There is
now emerging evidence that proceduralist-administered
sedation is feasible [11], safe [6], and cost effective [12].
However, it is unclear to what extent pulmonologists are
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now in charge of PSA, what their educational background
is, and what the current sedation practice entails.
More than 10 years ago, studies suggested the practice of
PSA during FB varied greatly for each physician [5, 8, 13].
Despite the wide use of FB among pulmonologists there is
little standardisation in practice and the choice of sedative
agents [5, 8, 13]. An increasing body of evidence suggests
that propofol (2,6-diisopropylphenol) is an eligible anaes-
thetic agent of choice for PSA during FB [7]. Propofol is a
potent hypnotic used for sedation in FB with a fast onset
and high degree of controllability [8]. It provokes at least
similar sedation, amnesia, and patient tolerance compared
with a combination of benzodiazepines and opiates [8].
However, there is no antagonist available and the thera-
peutic window is narrow. Therefore, the use of non-
anaesthesiologist administered propofol (NAAP) remains
controversial in several countries due to safety con-
cerns [7, 14]. In Switzerland, propofol is approved for
use without the strict legal restrictions applying in
some other countries enabling pulmonologists to use
it under the umbrella of local guidelines [15]. In con-
trast to other procedures e.g. gastroenterological endos-
copy it is unclear to what extent and under which
circumstances propofol is used in PSA during FB [16, 17].
The purpose of this study was: (i) to survey a repre-
sentative sample of Swiss pulmonologists; (ii) to assess
the current practice patterns of FBs; (iii) to focus on the
use of propofol and monitoring techniques.
Methods
Study population
A structured anonymous and standardised questionnaire
was sent to all members of the Swiss Society of Pulmo-
nology (n = 299) in their local language using the pub-
licly available database. We excluded participants who
did not perform FB in the previous 12 months, did not
complete >65 % of questions, or were paediatric pulmo-
nologists. Consequently only physicians (i.e. specialists/
consultants) in adult respiratory medicine who recently
performed FB in a practice or a hospital were analysed.
The survey was conducted from December 2014 until
April 2015.
Questionnaires
The questionnaire was based upon qualitative interviews
with experts in this field and earlier studies on PSA
[16, 17]. Participants were asked via e-mail to fill out a
web-based questionnaire (LamaPoll Berlin, Germany) and
state their answers according to their own (internal) docu-
mentation. Non-responders were sent a paper-version of
the questionnaire. The year of board certification as
specialist/consultant was used as a surrogate for length of
experience with FB. FB performed by a fellow under direct
supervision of a specialist/consultant were not included.
The questionnaire addressed the following areas: number
of procedures performed during the previous 12 months;
sedation rates; frequently used drugs for PSA; personnel
involved in PSA and route of drug delivery; use of supple-
mental oxygen and pharyngeal anaesthesia; frequency and
type of monitoring; availability of emergency resuscitative
measures; training of personnel involved in PSA; and the
incidence of complications attributed to sedation during
the previous 12 months. The following questions were
conditional on the use of propofol (either regularly or oc-
casionally): usage pattern for propofol (administration or
combination scheme); cumulative number of PSA carried
out with propofol; and the self-reported number of ad-
verse incidents necessitating emergency intervention dur-
ing sedation with propofol. In addition, responders were
asked to provide detailed qualitative feedback. Replies
were anonymous and non-traceable and IP addresses (i.e.
computer-numbers) were recorded to identify and delete
duplicate records.
Statistical analysis
Continuous data were summarised as mean ± SD or me-
dian (25th–75th percentiles) and categorical data summa-
rized using percentages. Continuous variables were
compared between groups using the Wilcoxon rank sum
test. The association between categorical variables was
assessed using Pearson’s χ2-test. Risk ratios obtained
using binomial regression with a log link function were
used to assess the effect of propofol use on various com-
plications adjusting for procedures per year and univer-
sity hospital (where patients with higher morbidities are
more likely to be seen). A two-sided significance level of
p < 0.05 was considered to be statistically significant.
Statistical analysis was performed using STATA version
14 (StataCorp LP, College Station, TX).
Ethics
Due to the nature of the study, approval from ethics-
committee was waived and a declaration of non-
objection was issued by the Cantonal Ethics Committee
of Zurich, Switzerland (KEK-ZH-Nr. 07-2015). Partici-
pants were informed that responding to the question-
naires was their consent to participate.
Results
Respondents
A total of 299 questionnaires and 83 reminders were
sent. The overall response rate was 78 %. After excluding
ineligible participants 167 questionnaires were analysed.
A detailed summary of the study flow is presented in
Fig. 1. The majority (80 %) of the online respondents
were German speaking, 18 % were French speaking, and
2 % Italian speaking. In total 27,150 FB from the last
year were analysed and respondents performed a median
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of 60 FB (IQR 30–150) annually. In the year prior to the
questionnaire being completed 2 deaths, 290 prolonged ap-
noeas, and 255 hypotensive events were reported during FB
(both defined by a necessary medical intervention). The re-
spondents had on average been board-certified for 14.8 ±
8.8 years. Figure 2 shows the professional background and
education of the participants. The overall FB-related mor-
tality rate was 7/100’000 FB. The sedation-related overall
morbidity rate (defined as needing a medical intervention
needed) was 0.02 %. The most common complications dur-
ing FB were apnoeas (defined as the need for bag-
ventilation) with a rate of 0.011 % and hypotonia (defined
as the need for intervention) with a rate of 0.009 %.
Sedation
Pulmonologists reported using sedatives or hypnotics in
a median of 100 % (IQR 90–100) of FBs. Propofol was
by far the most popular regularly used drug among Swiss
pulmonologists (77 %) either as a mono use (47 % of the
respondents) or in combination with other sedatives
(30 % of the respondents). A detailed distribution of the
frequency of drug use and combinations is shown in
Fig. 3. Proceduralists were mostly assisted by two staff
members (58 %) or one (41 %) during FB (1 % reported
more than 2 staff members).
Administration of drugs
The drugs were mostly administered by a nurse super-
vised by the bronchoscopist (73 %) less frequently by an
anaesthesiologist (14 %), the proceduralist him/her-self
(10 %), or other personnel (3 %). Most of the physicians
administered the drug via a peripheral venous catheter
either with sodium chloride (65 %) or without (12 %).
Other administration routes included: 13 % perfusor,
3 % direct intra-venous, 3 % intra-muscular, and 5 %
other administrations routes. In the case of propofol the
drug was administered in 70 % as a bolus and in 30 %
with the help of a perfusor.
Monitoring
The use of electronic monitoring by means of blood
pressure (87 %), pulse (95 %), and oxygen saturation
(98 %) is currently standard practice in Switzerland and
was routinely applied by the majority of respondents. In
patients with multiple comorbidities (e.g. patients with
lung diseases; obese patients; patients with obstructive
sleep apnoea) the monitoring rate was almost 100 %.
ECG (41 %) and capnography (10 %) was only applied in
selected patients. New emerging technologies like non-
invasive ventilation (3 %) and transcutaneous CO2-
monitoring (1 %) were only applied in specialised
299 Swiss pulmonologists 
were sent an invitation
167 questionnaires analysed 
(79% online, 21% paper)
51 did not perform FB in 2014
9 did not fill out > 65% of 
questions
7 were paediatric 
pulmonologists 
234 pulmonologists responded
(78% response rate)
65 did not respond
Fig 1 Flow chart of the study. An overall response rate of 78 % was
achieved by the use of online questionnaires and reminders
(hardcopies on paper) sent via post
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centres. The on-site availability of emergency measures
was: additional O2-tank (96 %), flumazenil (85 %), nalox-
one (77 %), atropine (83 %), oropharyngeal airway (72 %),
bag-valve-mask ventilation (96 %), tracheal intubation
(78 %), defibrillator (84 %), and resuscitation team (85 %).
Propofol
Propofol was the most commonly administered drug
during FB, without a significant preference of a certain
hospital type (Table 1). Anaesthesiologists used propofol
in 57 % of cases and were more likely to use propofol
when compared to non-anaesthesiologists (p = 0.023).
For 84 % of respondents propofol was used without the
attendance of an anaesthesiologist. Respondents who
used propofol in the last year reported using propofol
for a median of 5 years (IQR 2–6.5 years) and have per-
formed a median of 200 sedations (IQR 7.5–500) with
the drug in their career. During the past 12 months
approx. 21,140 procedures were carried out by respira-
tory physicians using propofol without the assistance of
an anaesthesiologist. Physicians who used propofol
(either alone or in combination with another drug)
performed more FB procedures per year when com-
pared to physicians who did not use propofol at all
(100 [IQR40–180] vs 45 [IQR 20–100]; p < 0.010) and
were also at an earlier stage of their career (Fig. 4).
The use of propofol could not be attributed to a specific
language region (p = 0.480) or discharge time (p = 0.695).
When adjusted for procedures per year (log trans-
formed) and university hospitals, the use of propofol
was not associated with reported apnoeas (RR = 1.32;
95 % CI 0.89–1.96; p = 0.17) or events of hypotension
(RR = 1.07; 95 % CI 0.69–1.67; p = 0.77) during the
procedure.
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Table 1 Summary statistics of propofol use by different hospital types
University hospital
(n = 22)
Cantonal hospital
(n = 30)
Regional/Private hospital
(n = 23)
Practice
(n = 21)
Propofol use, % 85 % 91 % 71 % 65 %
Bolus/Perfusor, % 68 % / 32 % 68 % / 32 % 92 % / 8 % 52 % / 48 %
Attendance of anaesthesiologists, % 9 % 3 % 0 % 43 %
Median number of procedures/year (IQR) 100 (50–450) 170 (130–300) 100 (40–150) 27 (15–50)
For this analysis, only respondents who were affiliated with only one hospital type were analysed (n = 96). While most of flexible bronchoscopies were performed
in cantonal hospitals anaesthesiologists mostly attended flexible bronchoscopies in a practice. IQR = Interquartile range
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Discussion
The administration of sedation during FB by the bron-
choscopist is controversial with large variations in differ-
ent countries. This survey assesses the current practice
patterns among most Swiss pulmonologists and gives in-
sights into the widespread use of propofol during FB in
Switzerland. It demonstrates a high heterogeneity in
PSA practice patterns which is influenced by local pref-
erences and was also observed in other studies [5, 13].
In contrast to earlier studies in this field, the current
study is distinct with regard to (i) the relatively high sed-
ation rate; (ii) the widespread use of propofol even in
private practice without the attendance of an anaesthesi-
ologist; (iii) and a high monitoring level [5, 13]. We hy-
pothesized that these findings can be attributed to a
shift in practice as well as country-specific preferences.
However, the results may also have important clinical
implications with regard to future education and bron-
choscopists in other countries who would like to change
their PSA patterns (e.g. towards the usage of propofol).
Safety results
The reported mortality and complication rate during FB
is generally low but comparable to other studies in this
field [18, 19]. The data suggests that FB is generally a
safe procedure associated with only few complications
and, surprisingly, the reported incidence of apnoeas in
our study was lower compared to gastro-intestinal en-
doscopies [17, 20]. A possible explanation for the diver-
ging complication rates to other specialities lies in the
fact that pulmonologists tend to have more knowledge
about airway management and breathing problems. Per-
haps, this could also be due to the fact that (compared
to Swiss gastroenterologists) the pulmonologists were
faced for the first time with a survey of this kind.
The use of propofol
The results confirm a trend towards propofol as an
agent of choice. In 1989 propofol was approved in
Switzerland and initially used around 2000 by non-
anaesthesiologists for gastro-intestinal endoscopy and FB
[15, 20]. Propofol has emerged as an appealing agent of
choice: it is better tolerated by patients with a faster re-
covery time and a quicker return to baseline mental sta-
tus [21–24]. The novelty of the drug and individual
familiarity with pre-existing regimens are also most
likely to be the reasons for a lower proportion of late-
career pulmonologists using propofol. Thus, the use of
propofol is predicted to rise in the future (Fig. 4). It is
important to keep in mind that in Switzerland, propofol
is approved for use without the strict legal limitations
that exist in some other countries. In particular, non-
anaesthesiologists are allowed to use propofol provided
they have had an adequate training for its use. For ex-
ample at the University Hospital Zurich in agreement
with the Institute of Anaesthesiology the following rec-
ommendations are given: First, the proceduralist should
not be the same person who is administering the drug.
Second, the patient should be adequately monitored (at
least oxygen saturation and blood pressure). Lastly, the
proceduralist and the drug administering person should
be capable of airway management and emergency venti-
lation. The rate of proceduralist-administered propofol
sedation of 84 % was also very high and, to our know-
ledge, the highest reported rate so far. However, world-
wide the use of NAAP remains controversial since
propofol lacks an available antagonist and its narrow
therapeutic window between no sedation and deep sed-
ation with apnoea warrants a formally trained physician.
Gastroenterologists in Switzerland have shown that
NAAP is safe, especially for gastro-intestinal endoscopy
[25]. In addition, other studies have shown that nurse-
administered propofol is a feasible and safe sedative
during FB [26]. Nevertheless, the cooperation between
anaesthesiologists and bronchoscopists remains crucial
[10]. Of those physicians who used propofol, 43 % reported
that they were actively supported or trained by an anaes-
thesiologist at the time of the introduction of the drug.
This is a very similar rate to Swiss gastroenterologists per-
forming endoscopy [17]. In general, our data suggest that
propofol administration represents a safe sedation tech-
nique that can be performed by a non-anaesthesiologist
[23]. This aspect is particularly relevant since the advan-
tages of propofol e.g. fast onset and high degree of control-
lability makes it a drug of choice for PSA during FB [8].
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Clinical implications
The study has some significant clinical implications.
First, the data gives insight into a health-care system
where the majority of pulmonologists are using propofol
for PSA during FB. It shows that NAAP is feasible and
can work on a large scale without an increased rate of
serious adverse events. Second, the study raises aware-
ness that these practice patterns clearly result in
augmented educational demands for pulmonologists
(specifically, training in NAAP) which should be taken
into account. It is vital that a bronchoscopist can facili-
tate every aspect of PSA during FB, especially adequate
and efficient therapy of complications.
The overwhelming part of qualitative feedback provided
in this study concerned the education of pulmonologists
in PSA and uncertainties regarding the competences of
proceduralists. Only 50 % of the respondents stated that
“systematic basic education” in the field of PSA was part
of their education. This is in line with other countries (e.g.
Italy [27]) and provides evidence for professional societies
and certifying agencies to move from a volume-based
certification system (which often implies “learning by
doing” [Fig. 2b]) to a standardised skill acquisition and
knowledge-based competency assessment, as already rec-
ommended by expert panels [28]. Currently, the European
guidelines state minimum numbers of supervised proce-
dures required for a trainee to be deemed competent [29].
A meta-analysis has shown that systematic FB-training
programs (ideally before exposure to patients) are effective
in terms of skills and behaviours in comparison with no
intervention and they can also be used to harmonise PSA
in the field of FB [30]. The skillset of future interventional
pulmonologists comprises the independent performance
of PSA during FB. This skill should not depend on poten-
tial rotations e.g. former rotations in the intensive care
unit but rather should be systematically trained [27].
Limitations and future studies
A limitation of this study is that the data are self-
reported and do not originate from registers. However,
by anonymising the questionnaire we sought to minim-
ise the underestimation of “unpleasant” data and encour-
age participants to accurately state their complication
numbers. On the other hand, because of the anonymity,
no further data beyond our questionnaire (e.g. circum-
stances of the two reported deaths, FB indications, pa-
tient data etc.) could be retrieved. The fact that the
response rate of this study (78 %) is higher than compar-
able studies [20] and that answers were retrieved from
all 15 major hospitals (five university hospitals and ten
cantonal hospitals) in Switzerland the authors feel
confident that the presented data are reliable and repre-
sent current clinical practice. Additionally, the observed
mortality rates are comparable to those from other
countries, a fact which promotes confidence in the re-
port of yet “unpleasant data” [18, 19]. Under the as-
sumption that sedation practice does not differ among
pulmonologists in each centre the “unknown” sedation
practice of the 22 % non-responders is likely to have a
negligible effect on the presented data. Finally, the study
represents only cross-sectional PSA practice patterns.
Experience in gastroenterological studies has also taught
us that sedation practice is constantly evolving and that
the picture of current sedation patterns can change dras-
tically within a relatively short time period [16, 17]. Al-
though we have tried to anticipate the future usage
patterns of propofol (Fig. 4), there is a need for further
evaluations (including electronic databases) in this field
to accurately assess shifts in PSA practice patterns. Since
the data is representative for Switzerland only, further
surveys in other countries are needed.
Conclusions
This representative survey of Swiss pulmonologists dem-
onstrates that the majority of Swiss pulmonologists are
in charge of PSA of their patients and describes in detail
the current sedation and monitoring practice. Propofol
was by far the most commonly administered drug during
FB in adults and the dominance in PSA of this drug is
likely to increase in the future. This study highlights the
need of education and systematic training of pulmonolo-
gists for PSA during FB.
Abbreviations
FB, flexible bronchoscopies; IQR, interquartile range; NAAP, non-anaesthesiologist
administered propofol; PSA, procedural sedation and analgesia; SD, standard
deviation
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